InventisBio Co (SHSE:688382) FCF Margin % : -1,052.39% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is InventisBio Co FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. InventisBio Co's Free Cash Flow for the three months ended in Mar. 2024 was ¥-90.6 Mil. InventisBio Co's Revenue for the three months ended in Mar. 2024 was ¥8.6 Mil. Therefore, InventisBio Co's FCF Margin % for the quarter that ended in Mar. 2024 was -1,052.39%.

As of today, InventisBio Co's current FCF Yield % is -6.97%.

The historical rank and industry rank for InventisBio Co's FCF Margin % or its related term are showing as below:

SHSE:688382' s FCF Margin % Range Over the Past 10 Years
Min: -169.27 Med: -112.49 Max: -55.7
Current: -165.34

During the past 6 years, the highest FCF Margin % of InventisBio Co was -55.70%. The lowest was -169.27%. And the median was -112.49%.

SHSE:688382's FCF Margin % is ranked worse than
52.34% of 1045 companies
in the Biotechnology industry
Industry Median: -139.31 vs SHSE:688382: -165.34

InventisBio Co FCF Margin % Historical Data

The historical data trend for InventisBio Co's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InventisBio Co FCF Margin % Chart

InventisBio Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-55.70

-169.27

InventisBio Co Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial												-	-153.27	-70.78	-127.50	-1,052.39

Competitive Comparison of InventisBio Co's FCF Margin %

For the Biotechnology subindustry, InventisBio Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InventisBio Co's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InventisBio Co's FCF Margin % distribution charts can be found below:

* The bar in red indicates where InventisBio Co's FCF Margin % falls into.

InventisBio Co FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

InventisBio Co's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-314.038	/	185.527
	=	-169.27 %

InventisBio Co's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-90.569	/	8.606
	=	-1,052.39 %

InventisBio Co FCF Margin % Related Terms

Thank you for viewing the detailed overview of InventisBio Co's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

InventisBio Co (SHSE:688382) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InventisBio Co Ltd (SHSE:688382) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 4, Lane 67, Li Bing Road, Room 210, Pilot Free Trade Zone, Shanghai, CHN, 201203

Website

http://www.inventisbio.com

InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of innovative targeted drugs with patent protection, covering non-small cell lung cancer, breast cancer, colorectal cancer and other solid tumors, as well as hyperuricemia and metabolic diseases such as gout.

InventisBio Co (SHSE:688382) Headlines

No Headlines